Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Exo Therapeutics logo — Advancing precision therapeutics for challenging pharmaceuti...

Exo Therapeutics

Advancing precision therapeutics for challenging pharmaceutical targets through pioneering technology and world-class research.

Founded 2018 11-50 employees Series B Total: $103.00M Biotechnology, Health Care +1

General Information

Company Name Exo Therapeutics
Founded Year 2018
Founders / Decision Makers
Team member
Employees 11-50
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Exo Therapeutics. To contact Exo Therapeutics, visit exo-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Exo Therapeutics compare?

A PDF of Exo Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Exo Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Exo Therapeutics

Exo Therapeutics, founded in 2018, is a promising biotechnology and pharmaceutical startup that is making waves in the industry with its innovative approach to drug discovery and development. The company's slogan, "Advancing precision therapeutics for challenging pharmaceutical targets through pioneering technology and world-class research," encapsulates its mission to address difficult pharmaceutical targets using cutting-edge technology. Exo Therapeutics' focus on small molecules and its utilization of the proprietary ExoSightTM platform sets it apart in the competitive pharmaceutical landscape. This platform allows the company to create a comprehensive pipeline of highly effective drug candidates that bind to exosites—distinct and distant binding pockets that can reprogram enzyme activity for precise therapeutic outcomes. The company's recent $78.00M Series B investment on 05 October 2021 has attracted significant attention from renowned investors such as CRV, Casdin Capital, Novartis Venture Fund, 6 Dimensions Capital, Newpath Partners, Nextech Invest, Samsara BioCapital, Morningside Venture Investments, and Biotechnology Value Fund. This influx of capital undoubtedly reflects the confidence in Exo Therapeutics' potential to revolutionize the treatment of challenging diseases, including oncology and inflammation. With a team of world-class researchers at the helm, Exo Therapeutics is poised to make substantial strides in developing breakthrough treatments and impacting the biotechnology, health care, and pharmaceutical industries positively. In summary, Exo Therapeutics is a startup with immense potential and a clear vision for pioneering precision therapeutics, making it a compelling prospect for investors seeking opportunities in the rapidly evolving pharmaceutical landscape.

Business keywords: Precision Therapeutics, Drug Discovery, Small Molecules, ExoSight Platform, Exosites, Enzyme Activity, Oncology, Inflammation, Pharmaceutical Targets, Therapeutic Outcomes, World-class Research, Pioneering Technology, Breakthrough Treatments, Deep Pipeline, Data-driven Research

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $78.00M 9
CRV Casdin Capital Novartis Venture Fund
CRV, Casdin Capital +7
05 Oct 2021
Series A $25.00M 1
Novartis Venture Fund
Novartis Venture Fund
16 Dec 2020

Latest News

View All
C&EN’s 10 Start-Ups to Watch for 2022 — Cen.acs.org
C&EN’s 10 Start-Ups to Watch for 2022
Cen.acs.org Nov 04, 2022

Exo Therapeutics Alternatives & Competitors

View All Alternatives
Exo Therapeutics vs
Revolution Medicines
Revolution Medicines United States

Translating Frontier Oncology Targets to Outsmart Cancer

IPO
1339 employees
Biotechnology, Health Care
Exo Therapeutics vs
EOLO PHARMA
EOLO PHARMA United States

Cutting-Edge Pharmacological Treatment for Obesity

Venture round
12 employees
Biopharma, Biotechnology
Exo Therapeutics vs
Flare Therapeutics
Flare Therapeutics United States

Trailblazing the path to drugging transcription factors to discover precision medicines for cancer &...

Series B
62 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Exo Therapeutics

Advancing precision therapeutics for challenging pharmaceutical targets through pioneering technology and world-class research.
Exo Therapeutics was founded in 2018.
Exo Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Precision Therapeutics, Drug Discovery, Small Molecules and ExoSight Platform.
Exo Therapeutics has approximately 11-50 employees.
Exo Therapeutics has completed 2 funding rounds, raising a total of $103.00M. The latest funding stage is Series B.
Top alternatives and competitors to Exo Therapeutics include Revolution Medicines, EOLO PHARMA, Flare Therapeutics, FogPharma, Degron Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Exo Therapeutics and Revolution Medicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Exo Therapeutics, https://bouncewatch.com/company/exo-therapeutics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout